REGULATORY CMC
Regulatory CMC strategy.
A clear plan for the evidence.
A filing decision needs more than a document checklist. Connect the scientific evidence, unresolved CMC questions and submission dependencies before committing to the next milestone.
When to bring in support
A new submission, a complex technical issue or a dossier assembled across different functions can leave important questions unresolved. Independent CMC review helps your team distinguish evidence gaps from presentation issues and prioritise what needs to happen next.
A defined starting point: CMC readiness assessment
Agree the product, submission stage, target markets and document set. Review the available CMC evidence against the agreed filing objective, then discuss the gaps and options with your technical team. The assessment can focus on selected topics rather than a complete dossier.
What you receive
- A prioritised evidence-gap register with the regulatory implications and dependencies.
- A submission-content plan identifying the documents and technical input required.
- A risk summary and recommended next steps for your programme team.
- A review discussion to align owners, decisions and follow-up actions.
Support beyond the assessment
Support can include CTD Modules 2.3 and 3 authoring and critical review, responses to CMC authority questions, and coordination of contributions from Quality, Manufacturing, Development and Supply. The workstream and review responsibilities are defined before delivery begins.
Product and team fit
Experience behind the consultancy spans small molecules, biologics, RNAi therapeutics and combination products. Support is available remotely for pharmaceutical and biotechnology teams, funded startups and CRO or consultancy partners needing a defined specialist workstream.
Scope before commitment
Fees, availability and milestones are agreed after an initial non-confidential discussion and review of the proposed scope. An assessment does not guarantee authority acceptance or approval. Confidential documents are exchanged under agreed arrangements.
A useful next step
Share a short, non-confidential outline of your product, markets and timeline.
Discuss your project